Coronavirus disease 2019 (COVID-19) has transformed into a worldwide challenge, since its outbreak in December 2019. Generally, patients with underlying medical conditions are at a higher risk of complications and fatality of pneumonias. Whether patients with systemic autoimmune diseases or vasculitides, are at increased risk for serious complications associated with COVID-19, is not established yet. Computed tomography (CT) has been employed as a diagnostic tool in the evaluation of patients with clinical suspicion of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection with a reported sensitivity of higher than reverse transcription polymerase chain reaction (RT-PCR) test. Multifocal bilateral ground-glass opacities (GGOs) with peripheral and posterior distribution and subsequent superimposition of consolidations are considered the main imaging features of the disease in chest CT. However, chest CT images of underlying rheumatologic or autoimmune diseases or vasculitides, such as systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis, Behçet disease, and granulomatosis with polyangiitis, especially those with extensive lung involvement can overshadow or obliterate features of COVID-19. In addition, CT findings of such diseases may resemble manifestations of COVID-19 (such as ground glass opacities with or without superimposed consolidation), making the diagnosis of viral infections, more challenging on imaging. Comparing the imaging findings with prior studies (if available) for any interval change is the most helpful approach. Otherwise, the diagnosis of COVID-19 in such patients must be cautiously made according to the clinical context and laboratory results, considering a very high clinical index of suspicion on imaging.

Keywords  COVID-19 · Pneumonia · Vasculitis · Granulomatosis polyangiitis · CT scan

Highlights

- The risk of COVID-19 and its associated complications is considered to be increased in patients with preexisting medical conditions such as rheumatic autoimmune disease or vasculitis.
- Chest CT with about 97% sensitivity has been extensively employed in the diagnosis and follow-up of patients with COVID-19, while RT-PCR with high specificity is the confirmative test. Chest CT has been playing a key role in many healthcare settings due to the inadequacy of laboratory kits for diagnosis and more availability of CT.
- Chest CT images of underlying rheumatologic conditions with pulmonary involvement, such as systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis, Behçet disease, and granulomatosis with polyangiitis, can obliterate or resemble features of COVID-19.
Diagnosis of COVID-19 in patients with underlying rheumatic autoimmune disease or vasculitis should be cautiously made according to the clinical context and RT-PCR results, considering a high clinical index of suspicion on imaging.

We discussed chest CT features in a number of patients with COVID-19 and underlying rheumatic diseases or vasculitis. There is a paucity of similar studies in the literature.

Introduction

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has transformed into a worldwide challenge, since its outbreak in December 2019. By March 11, World Health Organization (WHO) characterized coronavirus disease 2019 (COVID-19) as a pandemic [1], and as of July 21, over 14,500,000 confirmed cases have been recorded globally, claiming more than 607,000 lives [2]. COVID-19 presents with a range of clinical symptoms, including, but not limited to, dyspnea, cough, and constitutional symptoms. The intensity of symptoms and clinical manifestation of the disease varies from mild to severe, contingent on several factors, including but not limited to age, comorbidities, and integrity of the immune system as well as virological factors [3–6]. Like other chronic diseases, such as coronary heart disease, diabetes mellitus, hypertension, malignancies, chronic lung disease, asthma, human immunodeficiency virus (HIV) infection, liver disease, and chronic kidney disease [7], patients with rheumatic diseases are considered to be at an increased risk of respiratory infections and their complications [8, 9]. This may be due to disability and immune dysregulation. Immune modulating treatments and steroids also predispose patients to infection [10, 11]; however, some articles are against increased infection rate, higher risk of acute respiratory distress syndrome (ARDS), or other life threatening complications related to COVID-19 in rheumatologic patients [12, 13].

In a more severe type of COVID-19, uncontrolled and overwhelming release of cytokines, known as cytokine release syndrome (CRS) can lead to many pathological processes, suggesting that a severe immune reaction in the body can also be accountable for tissue damage, in addition to viral virulence. Cytokine release syndrome can also be induced by macrophage activation in patients with immune-related diseases and can be responsible for the immune pathogenesis of many pathological processes in these patients. Based on the similarity of the underlying pathogenesis of cytokine release in patients with COVID-19 and rheumatologic diseases, some overlap in imaging findings of these patients can be expected [14].

Clinical presentation, exposure history, reverse transcription polymerase chain reaction (RT-PCR) testing, and computed tomography (CT), each has their own diagnostic role in COVID-19, especially in the early stages of the disease [15]. Chest CT with about 97% sensitivity has been extensively employed in the diagnosis and follow-up of patients with COVID-19, while RT-PCR with high specificity is the confirmative test for the diagnosis. Although some scientific advisors do not agree with the role of chest CT as a routine screening modality in this setting, it has been playing a key role in many healthcare settings due to the inadequacy of laboratory kits for diagnosis and more availability of CT [16–19]. More recently, with the wide availability of RT-PCR kits, CT is mainly used for the evaluation of COVID-19 complications and suspect alternative diagnoses [20].

Chest CT findings in COVID-19 has been extensively discussed in literature. Multifocal bilateral ground-glass opacities (GGOs) with a peripheral and posterior distribution and later superimposition of consolidations are considered as the dominant radiologic picture of the disease [21, 22]. Less common findings of SARS-CoV-2 infection in CT include, CT halo sign, interlobular septal thickening, crazy paving pattern, bronchiectasis, pleural effusion, pericardial effusion, mediastinal lymphadenopathy [15, 23, 24], airway changes, reversed halo, vascular change as increased mural thickness or dilatation in involved region of parenchyma, and focal pleural thickening [25, 26]. In spite of numerous studies attempting to draw the map of CT characteristics in COVID-19, articles studying image characteristics in the patients with preexisting rheumatologic disease are of great scarcity [19].

Chest CT images of underlying rheumatologic conditions, especially those with pulmonary involvement, can overshadow or obliterate features of COVID-19, especially in the early stages of the infection. Radiologic features of lung involvement in rheumatic immune disease or vasculitis (usually as nonspecific interstitial pneumonitis-NSIP) can also simulate CT manifestations of COVID-19, considering numerous potential atypical manifestations of COVID-19. To address these issues, as an IRB approved retrospective cases series, we go over a number of cases of our tertiary hospital system with serologically confirmed COVID-19 pneumonia and underlying rheumatologic conditions or vasculitis and discuss their imaging picture. As the case series was performed retrospectively, the institutional review board waived informed consent.

Rheumatoid arthritis

While immunosuppressive medications, comorbidities, and immune dysregulation, in patients suffering from rheumatologic diseases lead to an increased risk of infection [10].
there is still uncertainty about the increased rate of COVID-19 and greater risk of complications in patients with rheumatoid arthritis (RA) [12]. Furthermore, the increasing knowledge about the pathological process of SARS-CoV-2 infection has resulted in some anti-rheumatoid medications such as Chloroquine and Hydroxychloroquine to be considered as a potentially effective option in the management of COVID-19 pneumonia [11].

Pulmonary involvement is a frequent extra-articular feature in RA. Among the radiologic findings of RA-related lung disease, GGOs and reticulations are the most common CT features. Other pulmonary findings include lung nodules, bronchiectasis, bronchiolitis, and those related to interstitial involvement, such as nonspecific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), and organizing pneumonia. Pericardial and pleural effusion are also frequently seen [27, 28].

Figure 1 demonstrates the chest CT images of a known case of rheumatoid arthritis with typical clinical symptoms and serological confirmation of COVID-19. The resemblance of CT findings in acute COVID-19 pneumonia and RA-related pulmonary disease indicates that diagnosis of COVID-19 in this group of patients should be cautiously made based on clinical context and mainly serologic data. In such cases, comparing the recent CT with any prior imaging, if available, can be most beneficial.

Systemic lupus erythematosus

While some articles argue against the increased risk of infection and a higher rate of ARDS or other severe complications associated to COVID-19 in patients suffering from systemic lupus erythematosus (SLE) [29], other studies are in favor of a more severe and complicated course of COVID-19 in this setting [30]. Further studies are needed to clarify the effect of SLE in the morbidity and mortality of COVID-19.

Pulmonary parenchyma is frequently involved in the course of SLE. Lung disease in SLE can be a notable cause of morbidity and mortality [31]. In a study by Li et al., the most common manifestations of thoracic involvement in SLE were interstitial pulmonary changes (including GGOs, honeycombing, subpleural lines, interstitial septal thickening, and emphysema) (66.67%), pleural disease (61.54%), parenchymal changes (including consolidation and patchy infiltration) (25.64%) and vascular changes (12.82%) [32]. Due to potential resemblance of presentations of COVID-19 pneumonia in chest

![Fig. 1 A 40-year-old woman with a history of rheumatoid arthritis for over 5 years presented with fever, dry cough, shortness of breath, and fatigue. Reverse transcription polymerase chain reaction was positive for SARS-CoV-2 infection. Axial chest CT a–c shows bilateral multifocal GGOs (arrows; a–c) and early consolidation in right middle lobe (dotted arrow; c), likely due to the patient’s known COVID-19. There is peribronchovascular thickening (arrowhead; a) and some subpleural reticulation (thin arrow; c) suggestive of interstitial pulmonary involvement secondary to underlying rheumatoid arthritis versus early superimposition of consolidation due to COVID-19. Differentiation is difficult and may need follow-up post-treatment imaging or comparison with any prior (pre-COVID-19) imaging, if available](image)
CT, with features of pulmonary involvement in SLE, differentiating these two entities can be challenging.

Figures 2 and 3 demonstrate the chest CT images of two known cases of SLE with clinical features and serological confirmation of COVID-19 pneumonia. Although Fig. 2 shows an atypical presentation of COVID-19 on imaging, Fig. 3 demonstrates a more typical imaging manifestation of the disease. Pleural thickening in Fig. 2 is more likely suggestive of SLE-related disease; however, pleural effusion and thickening can be infrequently seen in COVID-19 pneumonia.

**Systemic sclerosis**

Lung parenchyma is among the most important visceral organs that can be affected by the fibrotic process of collagen accumulation in systemic sclerosis (SSc). Pulmonary hypertension and Interstitial Lung Disease (ILD) are common manifestations of SSc and develop in near 75% of patients [33]. Patients with preexisting SSc, infected with SARS-CoV-2, can be at higher risk for fatal pulmonary complications, comparing to other autoimmune diseases, because of higher prevalence of pulmonary disease and common use of immune suppressive treatments [34].

Involvement of the heart in patients with SSc, due to primary cardiomyopathy or secondary to pulmonary
Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or hypertension, is associated with an increased rate of morbidity and mortality. Moreover, according to WHO, patients with underlying cardiovascular disease have increased susceptibility to SARS-CoV-2 infection and are prone to more severe disease with worse prognosis [32]. These facts call for more attention to dealing with SSc patients with respect to SARS-CoV-2 infection. In our search, there were only few articles dealing with COVID-19 in patients suffering from SSc and ILD, with only one providing chest CT information [35, 36].

Classically, SSc affects posterior, subpleural, and basilar portions of lungs, initially with subtle GGOs and reticular interstitial thickening in chest CT, which makes it very difficult to differentiate it from COVID-19. Many reported cases of COVID-19 pneumonia have resembled nonspecific interstitial pneumonitis (NSIP), as both tend to have peripheral and basilar ground glass opacities [24, 34]. However, in advanced stages of SSc, changes of scleroderma interstitial lung disease (SILD) may appear in CT, manifesting as fibrotic changes with decreased lungs volume, honeycomb cystic changes, traction bronchiectasis, and bronchiolectasis [37].

Figures 4 and 5 demonstrate the chest CT images of two known cases of systemic sclerosis and ILD with clinical manifestations, in favor of COVID-19 pneumonia. In the first case, chest CT findings of subpleural reticulation mostly in posterior segments of the lungs, traction bronchiectasis, and peribronchovascular thickening are mostly consistent with ILD in SSc. Bilateral patchy GGOs are nonspecific in this setting and may represent superimposed acute COVID-19 pneumonia versus secondary to the patient’s known inflammatory disease with possible pulmonary involvement. In the second case, there are some subpleural reticulation mostly consistent with interstitial involvement in SSc and sizeable bilateral pleural and pericardial effusion. Based on current literature, critically ill COVID-19 patients with preexisting comorbidities show a higher incidence of pericardial and pleural effusion, compared to the general population [38].

**Behçet disease**

Behçet disease is a rare multisystem and inflammatory disorder with an unknown cause. It is more common in young men, and in the Mediterranean descent. Uveitis and recurring genital and mouth ulcers are the typical triad of this disease. Joints, central nervous system, gastrointestinal system, pulmonary parenchyma, and cardiovascular system can also be affected in Behçet disease [39]. Both veins and arteries can be affected in the form of vasculitis, though veins are involved more frequently. Thoracic vascular involvement is
the most frequent cause of mortality. It happens in about 25–30% of cases and can display as pulmonary artery embolism, aneurysm of pulmonary artery, or thrombosis of vena cava [40]. Pleura and lung parenchyma are involved in 1–10% of cases. Pulmonary artery thrombosis and occlusion, because of vasculitis, may lead to hemorrhage and infarction. Parenchymal disease can manifest as pulmonary nodules, bronchiectasis, atelectasis, and interstitial lung disease. Less common manifestations of pulmonary involvement are fibrotic bands, emphysema, eosinophilic pneumonia, bronchitis, and small airway disease [39].

Behçet disease has been included in different classification systems ranging from vasculitis to rheumatic autoimmune, and spondyloarthropathies. Although few patients with vasculitis [41] or spondyloarthritis [42], infected with SARS-CoV-2 have been reported sporadically, we have not found any published report, dealing with COVID-19 in Behçet disease.

Figure 6 demonstrates the chest CT images of a known case of Behçet disease with clinical findings in favor of COVID-19 and laboratory-confirmed COVID-19 pneumonia. A patch of GGO is noted in the left upper lobe (thick arrow; b) and pericardial effusion (dotted arrow; d) which are uncommon findings of COVID-19 in general population, but can be more common in patients with preexisting disease. Small focal patchy GGO in the left lower lobe (thick arrow; b) is noted, which can be related to COVID-19 or secondary to compressive atelectasis. Although the RT-PCR test was negative in this patient, due to high clinical suspicion, living in an epidemic region, suboptimal sensitivity of serologic test and recuperation after 2 weeks, COVID-19 was the clinical diagnosis for this patient. Subpleural interstitial reticulation in left upper lobe is suggestive of scleroderma-related lung involvement (thin arrow; a). A soft tissue opacity in left anterior mediastinum (dotted arrow; c) is noted, suggestive of thymus hyperplasia, which can be related to underlying scleroderma. Evidence of esophageal dilatation (arrowhead; a) may be suggestive of scleroderma related esophagus involvement and warrants further evaluation. Cutaneous thickening of the right breast (arrowhead; d) is noted, which can be due to infectious/inflammatory diseases of lactation phase versus SSc-related skin change or neoplastic in etiology and warrants correlation with physical exam findings.
Granulomatosis with polyangiitis (wegener’s granulomatosis)

Granulomatosis with polyangiitis (GPA), is an uncommon necrotizing vasculitis that was previously known as Wegener’s granulomatosis. It presents with a clinical and pathological manifestations of upper airway, pulmonary, vascular, and renal system involvement. Many organs in the body can be involved; however, thoracic involvement in the course of the disease is the main problem. Poor or well-defined nodules of varying size, GGOs, consolidations, masses, and cavities are among common radiologic manifestations. Trachea and bronchial structures are also frequently involved. Tracheal involvement is usually seen as focal wall thickening or segmental stenosis. Distal airway involvement can present with bronchial wall thickening and bronchiectasis and may lead to pneumonia and atelectasis [43].

In Wegener’s granulomatosis, pleura, mediastinum, and heart are not affected commonly; however, pleural involvement most frequently manifests as pleural effusion. This can be due to affected pleura itself in the course of GPA or secondary to renal involvement. In up to 50% of lung nodules, cavitation can occur, especially in larger nodules with sizes over 2 cm. Hemorrhage in surrounding tissue of a nodule or cavity, can cause “halo sign” or “attoll sign” (reverse halo), respectively. Widespread ground-glass opacity and consolidation are also common findings in patients with GPA. Bilateral perihilar or peribronchovascular distribution is the most common pattern of GGOs. Ground-glass opacities and consolidations can disappear by time, similar to pulmonary nodules, regardless of therapy [43, 44].

Although our GPA patient in Fig. 7 demonstrates some nonspecific features that can be attributed to either COVID-19 or underlying autoimmune inflammatory disease, he also demonstrates typical findings of sino-nasal involvement in GPA, as an erosive osseous defect of nasal septum due to necrotizing vasculitis and signs of sinusitis. Nasal cavity and paranasal sinuses are involved in the course of GPA frequently. Due to decreased blood flow in the setting of vasculitis, tissue damage and nasal bone destruction can happen [45]. Due to resemblance of common pattern of pulmonary involvement in Granulomatosis with polyangiitis with typical findings of COVID-19 pneumonia, interpretation of chest CT of these patients should be made with special attention to distinctive patterns of each disease, consideration of clinical context, and emphasis on RT-PCR.

Conclusion

The risk of COVID-19 and its associated complications are increased in patients with preexisting medical conditions. Patients with rheumatologic diseases and vasculitis can be at an increased risk of infection, due to underlying impairment of immunity and adverse effects of corticosteroids or other immunosuppressive therapies on the immune system. Some imaging features of pulmonary involvement in these patients can mimic COVID-19. CT images of underlying morbidities may overshadow or obliterate features of COVID-19, especially in the early stages of the infection. Therefore, differentiation of superimposed infection with SARS-CoV-2 from underlying autoimmune pulmonary disease can be challenging, and the interpretation should be made in the context of serological data and clinical setting. Correlation of the imaging finding with those of the prior studies is most useful, if available.

However in majority of rheumatologic conditions, such as RA and SLE, there is no indication for pulmonary screening in asymptomatic patients. In these cases (like our reported patients), usually there is no prior/baseline

Fig. 6  A 35-year-old man with a known history of Behçet disease for 6 years, presented with fever and dyspnea. Reverse transcription polymerase chain reaction was positive for SARS-CoV-2. Axial chest CT a–c shows a faint patchy GGO in anterior segment of left upper lobe (arrow; a), which can be due to known SARS-Cov-2 infection or secondary to pulmonary involvement of Behcet. Small nodular opacity involving the paracardiac lingul is noted (arrow; b), most likely suggestive of parenchymal nodular disease of Behçet, as nodular disease is an uncommon manifestation of COVID-19. In mediastinal window, evidence of mild cardiomegaly is noticeable (arrow; c)
imaging for comparison and the diagnosis should mainly rely upon clinical and serological data. In some other rheumatologic conditions, that the primary pulmonary involvement resembles NSIP (such as scleroderma) or patchy ground glass appearance due to alveolar hemorrhage in Granulomatosis with Polyangiitis, sometimes differentiation is confusing. Therefore, differentiation of superimposed infection with SARS-CoV-2 from underlying autoimmune disease. Diffuse central bronchiectasis (thin arrow; a), subpleural soft tissue density, non-calcified mass of 35 × 25 mm in the paravertebral basal segment of right lower lobe (arrows; b, e), pericardial effusion (dotted arrow; d), nasal septal osseous defect (thin arrow; f), and suggestive signs of sinusitis such as soft tissue opacity in left maxillary sinus, as well as fluid level in right maxillary sinus (thick arrows; f) are noted. These findings are suggestive of involvement of lower airways, pulmonary parenchyma, pericardial, and sino-nasal structures related to granulomatosis with polyangiitis. However, pericardial effusion can also be a rare finding in COVID-19

Follow-up imaging is another useful tool to differentiate pulmonary infiltrations of rheumatologic disorders from infectious opacities of coronavirus pneumonia, as the former has a slow progression without appropriate therapy, while the latter (like most other infectious pneumonias) is more rapidly progressing or regressing. On the other hand, follow-up imaging to complete resolution of the inflammatory infiltrations is recommended, as this population is prone to long-term consequences of the coronavirus infection and residual pulmonary scarring [46, 47].

**Funding** None.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**References**

1. WHO Timeline—COVID-19 (2020) Who.int. 2020. https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19. Accessed 21 July 2020
2. COVID-19 situation reports (2020) Who.int. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 21 July 2020
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G,
Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or…

Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5. Erratum in: Lancet.

Liu K, Fang Y, Deng Y et al. (2020) Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 133(9):1025–1031. https://doi.org/10.1097/CMA.0000000000000744.

Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, Guo GY, Du J, Zheng CL, Zhu Q, Hu M, Li XY, Peng P, Shi HZ (2020) Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 55(5):2000524. https://doi.org/10.1183/13993003.00524-2020.

CDC COVID-19 Response Team (2020) Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 69(12):343–346. https://doi.org/10.15585/mmwr.mm6912e2.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3. Erratum in: Lancet.

Atzeni F, Masala IF, di Franco M, Sarzi-Puttini P (2017) Infections in rheumatoid arthritis.Curr Opin Rheumatol 29(4):323–330. https://doi.org/10.1097/BOR.0000000000000389.

Hsu CY, Ko CH, Wang JL, Hsu TC, Lin CY (2019) Comparison of the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study. Arthritis Res Ther 21(1):211. https://doi.org/10.1186/s13075-019-1977-5.

Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T, Michaud AJ, Filev PD, Hope MD, Jeudy J, Kligerman SJ, Henry TS (2020) Novel COronaVirus Disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and middle east respiratory syndrome. AJR Am J Roentgenol 16:1–4. https://doi.org/10.2214/AJR.20.23202.

Kooraki S, Hosseiny M, Myers L, Gholamrezanezhad A (2020) Coronavirus (COVID-19) outbreak: what is the burden of radiology? J Am Coll Radiol 17(4):447–451. https://doi.org/10.1016/j.jacr.2020.02.008.

Hosseiny M, Kooraki S, Gholamrezanezhad A, Reddy S, Myers L (2020) Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and middle east respiratory syndrome. AJR Am J Roentgenol 214(5):1078–1082. https://doi.org/10.2214/AJR.20.22969.

Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C (2020) Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 20(4):425–434.

Salehi S, Abedi A, Radmard AR, Sorouri M, Gholamrezanezhad A (2020) Chest computed tomography manifestation of coronavirus disease 2019 (COVID-19) in patients with cardiothoracic conditions. J Thorac Imaging. https://doi.org/10.1097/RTI.0000000000001297.

Ye Z, Zhang Y, Wang Y, Huang Z, Song B (2020) Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol 30(8):4381–4389.

Salehi S, Abedi A, Gholamrezanezhad A (2020) Reply to “vascular changes detected with thoracic CT in coronavirus disease (COVID-19) might be significant determinants for accurate diagnosis and optimal patient management”. AJR Am J Roentgenol. https://doi.org/10.2214/AJR.20.23339.

Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, Emoto T, Matsumoto T, Lynch DA (2004) Rheumatoid arthritis-related lung diseases: CT findings. Radiology 232(1):81–91. https://doi.org/10.1148/radiol.2321030174.

Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD, Tansescu R (2020) Extra-articular manifestations in rheumatoid arthritis. Lupus Sci Med 2020;7:1000027. https://doi.org/10.1177/2055116620943993.

Joeb B, Wiwanitkit V (2020) SLE, hydroxychloroquine and COVID-19: a comment. Ann Rheum Dis 20(4):425–434.

Sawalha AH, Zhao M, Cox P, Lu Q (2020) Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 215:108410. https://doi.org/10.1016/j.clinimm.2020.108410.

Kamen DL, Strange C (2010) Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med 31(3):479–488. https://doi.org/10.1016/j.ccm.2010.05.001.

Li P, Li S, Li L, Wang M (2017) Chest CT findings in systemic lupus erythematosus and its correlation with serum markers. Radiol Infect Dis 4(1):7–13.

Del Papa N, Sambataro G, Minniti A, Pignatello F, Caporali R (2020) Novel CoRoNaVirus Disease 2019 (COVID-19) epidemic: what are the risks for systemic sclerosis patients? Autoimmun Rev. https://doi.org/10.1016/j.autrev.2020.102558.

Matucci-Cerinic M, Bruni C, Allanore Y (2020) Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann Rheum Dis 79:724–726.
35. Cheng C, Li C, Zhao T, Yue J, Yang F, Yan Y, Liu X (2020) COVID-19 with rheumatic diseases: a report of 5 cases. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05160-x
36. Mihai C, Dobrota R, Schröder M, Garaiman A, Jordan S, Becker MO, Maurer B, Distler O (2020) COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis 79(5):668–669. https://doi.org/10.1136/annrheumdis-2020-217442
37. Strollo D, Goldin J (2010) Imaging lung disease in systemic sclerosis. Curr Rheumatol Rep 12(2):156–161. https://doi.org/10.1007/s11926-010-0095-0
38. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, Li C (2020) The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol 55(6):327–331. https://doi.org/10.1097/RLI.00000000000010672
39. Emad Y, Abdel-Razek N, Gheita T, El-Wakd M, El-Gohary T, Samadoni A (2007) Multislice CT pulmonary findings in Behçet’s disease (report of 16 cases). Clin Rheumatol 26(6):879–884. https://doi.org/10.1007/s10067-006-0408-x
40. Ceylan N, Bayraktaroglu S, Erturk SM, Savas R, Alper H (2010) Pulmonary and vascular manifestations of Behcet disease: imaging findings. AJR Am J Roentgenol 194(2):W158–W164. https://doi.org/10.2214/AJR.09.2763
41. Tomelleri A, Sartorelli S, Campochiaro C, Baldissera EM, Dagna L (2020) Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217600
42. Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, Sufka P, Grainger R, Wallace Z, Bhana S, Sirotich E, Liew J, Hausmann JS, Costello W, Robinson P, Machado PM, Yazdany J (2020) COVID-19 Global Rheumatology Alliance Steering Committee. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(20)30095-3
43. Martinez F, Chung JH, Digumarthy SR, Kanne JP, Abbott GF, Shepard JA, Mark EJ, Sharma A (2012) Common and uncommon manifestations of Wegener granulomatosis at chest CT: radiologic-pathologic correlation. Radiographics 32(1):51–69. https://doi.org/10.1148/rg.321115060
44. Cordier JF, Valeyre D, Guillevin L, Loire R, Brechot JM (1990) Pulmonary Wegener’s granulomatosis. A clinical and imaging study of 77 cases. Chest 97(4):906–912. https://doi.org/10.1378/chest.97.4.906
45. Wojciechowska J, Krajewski W, Krajewski P, Kręcicki T (2016) Granulomatosis with polyangiitis in otolaryngologist practice: a review of current knowledge. Clin Exp Otorhinolaryngol 9(1):8–13. https://doi.org/10.21053/ceo.2016.9.1.8
46. Salehi S, Reddy S, Gholamrezanezhad A (2020) Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19): what we know and what to expect. J Thorac Imaging 35(4):W87–W89
47. Katal S, Aghaghazvini L, Gholamrezanezhad A (2020) Chest-CT findings of COVID-19 in patients with pre-existing malignancies; a pictorial review. Clin Imaging 67:121–129. https://doi.org/10.1016/j.clinimag.2020.06.004

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.